A Study to Learn About New COVID-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (Substudy B)
A Phase 2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Vaccine Candidates for SARS-CoV-2 New Variants in Healthy Individuals
Category & Conditions: Coronavirus Disease (COVID-19)
Medicine: Comirnaty® (BNT162b2)
ClinicalTrials.gov Identifier (NCT): NCT05997290
Protocol ID: C4591054 (Substudy B)
Open Plain Language Summary Result:
Click here